Characterizing Oseltamivir Use among Community-Dwelling Patients Diagnosed with Influenza Virus Infection, 2023-2025

Clicks: 14
ID: 329397
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #259 of 316 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 316 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Oseltamivir is an antiviral medication for influenza that can reduce the duration of symptoms and may lower the risk of some complications. Recommendations for use of oseltamivir include in the outpatient setting for individuals at higher risk of developing influenza complications. Objectives To describe oseltamivir initiation and treatment completion among influenza-positive outpatients and identify factors associated with each. Methods In a U.S. outpatient household transmission study, index participants with laboratory-confirmed influenza provided up to 12 days of detailed information on medication use. We described oseltamivir initiation among index cases and treatment course completion of ≥ 10 doses among cases who initiated oseltamivir. We used adjusted logistic regression to identify factors associated with initiation and course completion. Results Among 823 enrolled index cases, 324 (39%) initiated oseltamivir treatment. Of 406 persons at higher risk for influenza complications, 172 (42%) initiated treatment. Oseltamivir initiation was lowest among children aged 2-4 years (19%) compared to all other age groups. After excluding the likely censored cases, 133/313 cases (42%) completed the recommended treatment course. Among 163 individuals at higher risk of influenza complications, 69 (42%) completed the recommended treatment course. Children < 2 years were significantly less likely to complete treatment compared to adults aged 18-50 years (aOR: 0.21, 95% CI: 0.04, 0.78, p=0.030); reasons for discontinuation could not be determined. Conclusions In this population in the outpatient setting, fewer than half of persons at higher risk for influenza complications initiated oseltamivir treatment, and fewer than half of those who initiated completed treatment.
Reference Key
openalex_W7213987387 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Emily McNair, Jennie H Kwon, Carlos G Grijalva, Son H. McLaren, Jessica E. Deyoe, Samantha Dean, Lydia Bristol, Elizabeth B. White, Stephanie A. Fritz, Rachel M. Presti, Caroline A. O'Neil, Ellen Sano, Celibell Vargas, Jonathan Schmitz, Yuwei Zhu, Theresa A Scott, Stacey House, H Keipp Talbot, Melissa S. Stockwell, Alexandra M. Mellis, Rvtn Flu study group, Kim T. Vu, Regine Burton, Francesca Yerbic, Lucy Vogt, Carleigh Samuels, Kelly Bono, Olivia Arter, Alyssa Valencia, Elianora Ovchiyan, Akshay Saluja, Mengesha Teshome, Alexandra Astarita, Sara Hubert, Tina Robinson, Mary G. Boyle, Alaina Schneider, Lisa Richardson, Tara Curley, Jamie Mills, Elizabeth Capasso-Gulve, Sarah Pruitt-Welsh, Sam Kerz, Heena Kahn, Jamie Garner, Judy A. King, Erica Anderson, Brianna Schibley-Laird, Rebecca Tablada, Onika Abrams, Sydney A Cornelison, Dandan Liu, Liqun Wang, Anny L Diaz Perez, Raul A Silverio Francisco, Ana Valdez de Romero
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag587
URL
https://doi.org/10.1093/ofid/ofag587
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.